Get the content you want anytime you want.

Top 5 Contagion® News Articles for May 2017

JUN 08, 2017 | SARAH ANWAR

#3: Changes in Therapy Guideline for Nosocomial Pneumonia

It has been 11 years since the first guideline for nosocomial pneumonia was jointly published by The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS).
IDSA and ATS have made 7 key updates to the guidelines. These include changes to classification of healthcare-associated pneumonia, which was originally placed under the spectrum of hospital-acquired pneumonia and ventilator-acquired pneumonia, due to a concern over risk of infections with multidrug-resistant pathogens in this population. After reviewing more recent data, however, it was seen that these patients are, in fact, not at increased risk for infection with multidrug-resistant infections. Therefore, healthcare-associated pneumonia has been reclassified under community-acquired pneumonia.
The updated guidelines also highlights risk factors for multidrug-resistant pathogens, as well as recommendations for empiric antipseudomonal agents for those at high risk for multidrug-resistant pathogens.
Read more about the updated pneumonia guidelines.

#2: Is the Medical Community Behind the Times When It Comes to Treating Lyme?

According to the CDC, in 2015, approximately 400,000 new individuals were diagnosed with Lyme disease in the United States, where the tick-borne disease has been recognized for more than 40 years. In addition, the United States also recognized 19 tick-borne diseases, some of which can be transmitted simultaneously from the bite of one infected tick.
The subject of chronic Lyme disease is a controversial one; however, according to a study published in PLOS ONE, between 36% and 63% of individuals who acquired Lyme disease go on to develop a chronic form of infection (post-treatment Lyme disease).
In addition, clinical practice guidelines for Lyme disease appear to be outdated and not included in the National Guidelines Clearinghouse (NGC). In addition, “These guidelines are most often used to deny treatment to patients with chronic disease, and so their current absence from the NGC is beneficial to patients who may need long-term antibiotic therapy and have been denied this through use of these guidelines.”
Read more about Lyme testing, treatment and legislation.

Big advances in treatment can